Volume 125, Issue 4, Pages (October 2003)

Slides:

Advertisements

Similar presentations

Genetic testing for high-risk colon cancer patients1 William M. Grady Gastroenterology Volume 124, Issue 6, Pages (May 2003) DOI: /S (03)

Advertisements

Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Irbesartan, an angiotensin type 1 receptor inhibitor,

Volume 137, Issue 4, Pages (October 2009)

Eoin O’Brien, DSc, MD, Eamon Dolan, MD, FRCPI Clinical Therapeutics

Volume 149, Issue 2, Pages e2 (August 2015)

Volume 94, Issue 4, Pages (October 1988)

A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis Maria Theresa Arias, Niels Vande Casteele, Séverine Vermeire,

Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis Konstantinos.

Volume 127, Issue 4, Pages (October 2004)

Volume 134, Issue 7, Pages (June 2008)

Volume 123, Issue 1, Pages (July 2002)

Ashwin N. Ananthakrishnan, Millie D. Long, Christopher F

Volume 138, Issue 2, Pages (February 2010)

Abatacept for Crohn's Disease and Ulcerative Colitis

Volume 135, Issue 4, Pages (October 2008)

Volume 143, Issue 2, Pages e1 (August 2012)

Covering the Cover Gastroenterology

A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis Maria Theresa Arias, Niels Vande Casteele, Séverine Vermeire,

Volume 132, Issue 1, Pages (January 2007)

Brian W. Sipe, Mark Scheidler, Arthur Baluyut, Betty Wright

Celecoxib Plus Aspirin Versus Naproxen and Lansoprazole Plus Aspirin: A Randomized, Double-Blind, Endoscopic Trial Jay L. Goldstein, Byron Cryer, Fouad.

Pushing the Pedal to the Metal: Should We Accelerate Infliximab Therapy for Patients With Severe Ulcerative Colitis? Hans H. Herfarth, MD, PhD Clinical.

Long-term outcome after infliximab for refractory ulcerative colitis

Genetic variants in autophagy-related genes and granuloma formation in a cohort of surgically treated Crohn's disease patients Marko Brinar, Séverine.

Volume 120, Issue 6, Pages (May 2001)

Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease Matthias Jürgens, Jestinah M. Mahachie.

Volume 134, Issue 7, Pages (June 2008)

Volume 116, Issue 1, Pages (January 1999)

Volume 127, Issue 4, Pages (October 2004)

Tetsuro Tsujimoto, Hiroshi Kajio International Journal of Cardiology

Volume 148, Issue 7, Pages e3 (June 2015)

Randomized Double-Blind Study of the Safety and Immunogenicity of Standard-Dose Trivalent Inactivated Influenza Vaccine versus High-Dose Trivalent Inactivated.

Salt and Hypertension American Journal of Kidney Diseases

PATHWAY-2: spironolactone for resistant hypertension – Authors' reply

Safety of Celecoxib in Patients With Ulcerative Colitis in Remission: A Randomized, Placebo-Controlled, Pilot Study William J. Sandborn, William F. Stenson,

Severe Constipation Clinical Gastroenterology and Hepatology

Ronnie Fass, Stephen J. Sontag, Barry Traxler, Mark Sostek

Volume 137, Issue 4, Pages (October 2009)

Protein-Losing Enteropathy in Crohn’s Disease

Implementing the Concept of Continuous Clinical Response Into Clinical Practice for Ulcerative Colitis Laurent Peyrin-Biroulet, Gert Van Assche, Alessandro.

Volume 147, Issue 6, Pages e5 (December 2014)

Volume 132, Issue 1, Pages (January 2007)

Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis Konstantinos.

Volume 135, Issue 5, Pages (November 2008)

Paul J. Martin, Terry Furlong, Scott D. Rowley, Steven A

A Phase I/II Study of Mycophenolate Mofetil in Combination with Cyclosporine for Prophylaxis of Acute Graft-versus-Host Disease after Myeloablative Conditioning.

Volume 149, Issue 6, Pages (June 2016)

Volume 136, Issue 7, Pages (June 2009)

Long-Term Monitoring of Infliximab Therapy for Perianal Fistulizing Crohn's Disease by Using Magnetic Resonance Imaging Konstantinos Karmiris, Didier.

Volume 384, Issue 9940, Pages (July 2014)

Volume 135, Issue 1, Pages (July 2008)

Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises Andrew M. Atz, MDa, Amy K. Lefler, PharmDb, David.

Volume 150, Issue 5, Pages (May 2016)

Recent experience with high-dose intravenous iron administration

Genetic Risk Profiling and Prediction of Disease Course in Crohn's Disease Patients Liesbet Henckaerts, Kristel Van Steen, Isabel Verstreken, Isabelle.

Volume 62, Issue 5, Pages (November 2002)

Volume 126, Issue 2, Pages (February 2004)

Incidence of Colectomy During Long-term Follow-up After Cyclosporine-Induced Remission of Severe Ulcerative Colitis David N. Moskovitz, Gert Van Assche,

Volume 142, Issue 5, Pages e2 (May 2012)

Volume 117, Issue 4, Pages (October 1999)

Volume 122, Issue 1, Pages (January 2002)

A 27-Year-Old Woman With Constipation: Diagnosis and Treatment

Volume 142, Issue 2, Pages e3 (February 2012)

Volume 56, Issue 2, Pages (August 1999)

Volume 127, Issue 4, Pages (October 2004)

Volume 125, Issue 1, Pages (July 2003)

Nathaniel P Katz, MD Journal of Pain and Symptom Management

Issue Highlights Clinical Gastroenterology and Hepatology

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis Jean-Frédéric Colombel,

Presentation transcript:

Volume 125, Issue 4, Pages 1025-1031 (October 2003) Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis1 Gert Van Assche, Geert D’haens, Maja Noman, Séverine Vermeire, Martin Hiele, Katrien Asnong, Joris Arts, Andre D’hoore, Freddy Penninckx, Paul Rutgeerts Gastroenterology Volume 125, Issue 4, Pages 1025-1031 (October 2003) DOI: 10.1016/S0016-5085(03)01214-9

Figure 1 Cumulative response to IV cycloporine in the 2 treatment groups. The percentage of responding patients is expressed at daily intervals from D0 to D8. Gastroenterology 2003 125, 1025-1031DOI: (10.1016/S0016-5085(03)01214-9)

Figure 2 Difference in mean cyclosporine doses and blood concentrations between the 2 treatment groups. Data are expressed as means ± SD. Blood levels were strictly controlled to vary between 150 and 250 ng/mL for the 2-mg/kg group and 250 and 350 for the 4-mg/kg group. Gastroenterology 2003 125, 1025-1031DOI: (10.1016/S0016-5085(03)01214-9)

Figure 3 Novel cases of diastolic hypertension in the 2 treatment groups. Diastolic hypertension was defined as a diastolic blood pressure of >90 mm Hg for at least 2 days from D1 to D8. Gastroenterology 2003 125, 1025-1031DOI: (10.1016/S0016-5085(03)01214-9)